康諾亞生物醫藥科技有限公司（香港联交所股票代码：02162）于2026年2月2日发布截至2026年1月31日的股份变动月报表。根据公告，公司本月并未发生新的股份发行、回购或注销活动，股本结构保持稳定。
本次报告显示，公司法定注册股本维持在500,000,000股，面值每股USD 0.0001，注册股本总额USD 50,000。普通股已发行股份总数保持在298,735,566股，较上月无变化；并无库藏股和其他类型股份的变动记录。
公司同时确认符合香港联交所对于公众持股量的相关要求。本月报告亦未披露期权及其他激励计划的新增或行使情况。
公告由执行董事Bo CHEN博士签署，公司表示将严格遵循香港联交所《上市规则》及相关法律法规。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.